查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1602792

抗缺血药物市场：按类型、适应症、给药途径和最终用户分类 - 全球预测 2025-2030

Anti-Ischemic Agents Market by Type (Antiplatelet Agents, Calcium Channel Blockers, Organic Nitrates), Indication (Angina Pectoris, Ischemic Stroke, Myocardial Infarction), Route of Administration, End-User - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 191 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

2023年抗缺血药物市值为35,588万美元，预计2024年将达到37899万美元，复合年增长率为6.23%，预计到2030年将达到54343万美元。

抗缺血药物是一种旨在改善心臟血流量和氧气输送并缓解心绞痛等缺血症状的药物。它们是一系列广泛的治疗方法，旨在控制冠状动脉疾病、心臟病和其他限制心肌血流的心血管疾病。全球心血管疾病盛行率的上升凸显了对抗缺血药物的需求，心血管疾病是导致死亡的主要原因。抗缺血药物在医院、诊所和门诊治疗中心有着广泛的应用，循环系统经常使用它来预防心臟衰竭，并作为心臟病发作后的治疗策略。最终用途范围从改善急性护理中的患者治疗效果到门诊护理中的慢性管理。

主要市场统计
基准年[2023] 35588万美元
预测年份 [2024] 37899万美元
预测年份 [2030] 5.4343亿美元
复合年增长率（%） 6.23%

市场成长受到文明病盛行率增加、药物配方进步以及医疗保健支出增加等因素的影响。个人化医疗的创新以及雷诺嗪和Ivabradine等新治疗类别的出现为市场扩张提供了机会。医疗保健系统不断发展的新兴市场也具有巨大的市场渗透潜力。然而，市场面临严格的监管要求、高昂的研发成本以及替代疗法（包括血管成形术等侵入性手术）的可用性等挑战。

创新的机会在于开发功效较强、副作用较少、作用机转新颖的药物。生技药品和基因疗法为未来的研究和开发带来了希望。将数位健康技术与抗缺血治疗相结合也是一个新兴的创新领域，有可能提高患者的依从性和治疗结果。您可以透过专注于特定的未满足需求开拓利基市场，例如罕见的缺血性疾病，在该领域，现有製药公司在竞争格局中占据主导地位。总体而言，市场仍然充满活力，技术进步和人口变化为显着的业务成长和持续的研究工作提供了管道。

市场动态：揭示快速发展的抗缺血药物市场的关键市场洞察

供需的动态交互作用正在改变抗缺血药物市场。了解这些不断变化的市场动态可以帮助企业做出明智的投资决策、策略决策并抓住新的商机。全面了解这些趋势可以帮助企业降低政治、地理、技术、社会和经济领域的风险，同时也能帮助企业了解消费行为及其对製造业的影响。

  • 市场驱动因素
    • 生活方式的改变和缺血性疾病盛行率的上升
    • 更多地使用先进的诊断工具和技术来治疗缺血性疾病
    • 开发新型抗缺血药物的研究活动激增
  • 市场限制因素
    • 治疗费用上涨
  • 市场机会
    • 药物开发活动的持续创新与投资
    • 临床试验中各相关人员之间的合作
  • 市场挑战
    • 相关副作用与安全性问题

波特五力：驾驭抗缺血药物市场的策略工具

波特的五力框架是理解市场竞争格局的重要工具。波特的五力框架为评估公司的竞争地位和探索策略机会提供了清晰的方法。该框架可帮助公司评估市场动态并确定新业务的盈利。这些见解使公司能够利用自己的优势，解决弱点并避免潜在的挑战，从而确保更强大的市场地位。

PESTLE分析：了解抗缺血药物市场的外部影响

外部宏观环境因素在塑造抗缺血药物市场的表现动态中发挥着至关重要的作用。对政治、经济、社会、技术、法律和环境因素的分析提供了应对这些影响所需的资讯。透过调查 PESTLE 因素，公司可以更了解潜在的风险和机会。这种分析可以帮助公司预测法规、消费者偏好和经济趋势的变化，并帮助他们做出积极主动的决策。

市场占有率分析 了解抗缺血药物市场竞争状况

抗缺血药物市场的详细市场占有率分析可以对供应商的绩效进行全面评估。公司可以透过比较收益、客户群和成长率等关键指标来揭示其竞争地位。该分析揭示了市场集中、分散和整合的趋势，为供应商提供了製定策略决策所需的洞察力，以应对日益激烈的竞争。

FPNV定位矩阵抗缺血剂市场供应商绩效评估

FPNV定位矩阵是评估抗缺血药物市场供应商的重要工具。此矩阵允许业务组织根据商务策略和产品满意度评估供应商，从而做出与其目标相符的明智决策。这四个象限使您能够清晰、准确地划分供应商，以确定最能满足您的策略目标的合作伙伴和解决方案。

策略分析与建议，描绘抗缺血药物市场的成功之路

对于旨在加强其在全球市场的影响力的公司来说，抗缺血药物市场的策略分析至关重要。透过审查关键资源、能力和绩效指标，公司可以识别成长机会并努力改进。这种方法使您能够克服竞争环境中的挑战，利用新的商机并取得长期成功。

本报告对市场进行了全面分析，涵盖关键重点领域：

1. 市场渗透率：详细检视当前市场环境、主要企业的广泛资料、评估其在市场中的影响力和整体影响力。

2. 市场开拓：辨识新兴市场的成长机会，评估现有领域的扩张潜力，并提供未来成长的策略蓝图。

3. 市场多元化：分析近期产品发布、开拓地区、关键产业进展、塑造市场的策略投资。

4. 竞争评估与情报：彻底分析竞争格局，检验市场占有率、业务策略、产品系列、认证、监理核准、专利趋势、主要企业的技术进步等。

5. 产品开发与创新：重点在于有望推动未来市场成长的最尖端科技、研发活动和产品创新。

我们也回答重要问题，以帮助相关人员做出明智的决策：

1.目前的市场规模和未来的成长预测是多少？

2. 哪些产品、区隔市场和地区提供最佳投资机会？

3.塑造市场的主要技术趋势和监管影响是什么？

4.主要厂商的市场占有率和竞争地位如何？

5. 推动供应商市场进入和退出策略的收益来源和策略机会是什么？

目录

第一章 前言

第二章调查方法

第三章执行摘要

第四章市场概况

第五章市场洞察

  • 市场动态
    • 促进因素
      • 生活方式的改变和缺血性疾病发生率的增加
      • 更多使用先进的缺血性疾病诊断工具和技术
      • 旨在开发新型抗缺血药物的研究活动迅速增加
    • 抑制因素
      • 治疗费用高
    • 机会
      • 药物开发活动的持续创新与投资
      • 临床试验中各相关人员的合作
    • 任务
      • 相关副作用与安全性问题
  • 市场区隔分析
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 经济
    • 社群
    • 技术的
    • 合法地
    • 环境

第六章 抗缺血药物市场：依类型

  • 抗血小板药
  • 钙离子通道阻断剂
  • 有机硝酸盐
  • 钾通道开放剂
  • B阻断剂

第七章 抗缺血药物适应症市场

  • 心绞痛
  • 缺血性中风
  • 心肌梗塞
  • 周边动脉疾病

第八章抗缺血药物市场：依给药途径

  • 静脉注射 (IV)
  • 口服
  • 经皮的

第九章抗缺血药物市场：依最终用户分类

  • 门诊治疗
  • 居家护理
  • 医院

第十章 美洲抗缺血药物市场

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美国

第十一章 亚太地区抗缺血药物市场

  • 澳洲
  • 中国
  • 印度
  • 印尼
  • 日本
  • 马来西亚
  • 菲律宾
  • 新加坡
  • 韩国
  • 台湾
  • 泰国
  • 越南

第十二章 欧洲、中东和非洲抗缺血药物市场

  • 丹麦
  • 埃及
  • 芬兰
  • 法国
  • 德国
  • 以色列
  • 义大利
  • 荷兰
  • 奈及利亚
  • 挪威
  • 波兰
  • 卡达
  • 俄罗斯
  • 沙乌地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公国
  • 英国

第十三章竞争格局

  • 2023 年市场占有率分析
  • FPNV 定位矩阵，2023
  • 竞争情境分析
  • 战略分析和建议

公司名单

  • Alembic Pharmaceuticals Limited
  • AstraZeneca
  • Baxter, Inc.
  • Bayer AG
  • Boehringer Ingelheim
  • Bristol Myers Squibb
  • Cipla Ltd.
  • Dr Reddy's Laboratories Ltd.
  • Eli Lily & Company
  • Eris Lifesciences Ltd.
  • FDC Ltd.
  • Glenmark Pharmaceuticals Ltd.
  • Intas Pharmaceuticals Ltd.
  • Ipca Laboratories Ltd.
  • JB Chemicals and Pharmaceuticals Ltd.
  • Lupin Ltd.
  • Macleods Pharmaceuticals Pvt Ltd.
  • Medley Pharmaceuticals Ltd.
  • Micro Labs Ltd.
  • Natco Pharma Ltd.
  • Novartis AG
  • Pfizer, Inc.
  • Torrent Pharmaceuticals Ltd.
  • Troikaa Pharmaceuticals Ltd.
  • Zydus Lifesciences Ltd.
Product Code: MRR-8E22B6193309

The Anti-Ischemic Agents Market was valued at USD 355.88 million in 2023, expected to reach USD 378.99 million in 2024, and is projected to grow at a CAGR of 6.23%, to USD 543.43 million by 2030.

Anti-ischemic agents are pharmaceuticals designed to improve blood flow and oxygen supply to the heart, alleviating symptoms of ischemia such as angina. The scope of these agents encompasses a range of therapeutic applications aimed at managing coronary artery disease, heart attacks, and other cardiovascular conditions where blood flow to the heart muscle is restricted. The necessity for anti-ischemic agents is underscored by the rising prevalence of cardiovascular diseases globally, which are the leading cause of mortality. Their application spans hospitals, clinics, and ambulatory care centers, often utilized by cardiologists to prevent heart failure or in management strategies post-heart attack. The end-use scope extends from enhancing patient outcomes in acute care settings to chronic management in outpatient care.

KEY MARKET STATISTICS
Base Year [2023] USD 355.88 million
Estimated Year [2024] USD 378.99 million
Forecast Year [2030] USD 543.43 million
CAGR (%) 6.23%

Market growth is influenced by factors such as increasing incidence of lifestyle diseases, advancements in drug formulation, and rising healthcare expenditures. Innovations in personalized medicine and the advent of novel therapeutic classes, such as ranolazine and ivabradine, present opportunities for expanding the market. Emerging markets, with growing healthcare systems, also offer significant potential for market penetration. However, the market faces challenges like stringent regulatory requirements, high research and development costs, and the availability of alternative treatments, including invasive procedures like angioplasty.

Opportunities for innovation lie in developing drugs with better efficacy, fewer side effects, and novel mechanisms of action. Biologics and gene therapy hold promise for future research and development. Combining digital health technologies with anti-ischemic treatments also represents a burgeoning area for innovation, potentially improving patient adherence and outcomes. Despite the competitive landscape dominated by established pharmaceutical companies, niche markets can be explored by focusing on specific unmet needs, such as rare ischemic conditions. Overall, the market remains dynamic, with technological advancements and shifting demographics providing channels for significant business growth and sustained research efforts.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Anti-Ischemic Agents Market

The Anti-Ischemic Agents Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Changing lifestyles and rising prevalence of ischemic conditions
    • Increasing utilization of advanced diagnostic tools and techniques for ischemic conditions
    • Surge in research activities for developing new anti-ischemic agents
  • Market Restraints
    • High cost of treatment
  • Market Opportunities
    • Ongoing innovations and investment in drug development activities
    • Collaborative efforts among various stakeholders for clinical trials
  • Market Challenges
    • Associated side-effects and safety concerns

Porter's Five Forces: A Strategic Tool for Navigating the Anti-Ischemic Agents Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Anti-Ischemic Agents Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Anti-Ischemic Agents Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Anti-Ischemic Agents Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Anti-Ischemic Agents Market

A detailed market share analysis in the Anti-Ischemic Agents Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Anti-Ischemic Agents Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Anti-Ischemic Agents Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Anti-Ischemic Agents Market

A strategic analysis of the Anti-Ischemic Agents Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Anti-Ischemic Agents Market, highlighting leading vendors and their innovative profiles. These include Alembic Pharmaceuticals Limited, AstraZeneca, Baxter, Inc., Bayer AG, Boehringer Ingelheim, Bristol Myers Squibb, Cipla Ltd., Dr Reddy's Laboratories Ltd., Eli Lily & Company, Eris Lifesciences Ltd., FDC Ltd., Glenmark Pharmaceuticals Ltd., Intas Pharmaceuticals Ltd., Ipca Laboratories Ltd., J B Chemicals and Pharmaceuticals Ltd., Lupin Ltd., Macleods Pharmaceuticals Pvt Ltd., Medley Pharmaceuticals Ltd., Micro Labs Ltd., Natco Pharma Ltd., Novartis AG, Pfizer, Inc., Torrent Pharmaceuticals Ltd., Troikaa Pharmaceuticals Ltd., and Zydus Lifesciences Ltd..

Market Segmentation & Coverage

This research report categorizes the Anti-Ischemic Agents Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Type, market is studied across Antiplatelet Agents, Calcium Channel Blockers, Organic Nitrates, Potassium Channel Openers, and B-Blockers.
  • Based on Indication, market is studied across Angina Pectoris, Ischemic Stroke, Myocardial Infarction, and Peripheral Artery Diseases.
  • Based on Route of Administration, market is studied across Intravenous (IV), Oral, and Transdermal.
  • Based on End-User, market is studied across Ambulatory Care, Homecare, and Hospitals.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Changing lifestyles and rising prevalence of ischemic conditions
      • 5.1.1.2. Increasing utilization of advanced diagnostic tools and techniques for ischemic conditions
      • 5.1.1.3. Surge in research activities for developing new anti-ischemic agents
    • 5.1.2. Restraints
      • 5.1.2.1. High cost of treatment
    • 5.1.3. Opportunities
      • 5.1.3.1. Ongoing innovations and investment in drug development activities
      • 5.1.3.2. Collaborative efforts among various stakeholders for clinical trials
    • 5.1.4. Challenges
      • 5.1.4.1. Associated side-effects and safety concerns
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Anti-Ischemic Agents Market, by Type

  • 6.1. Introduction
  • 6.2. Antiplatelet Agents
  • 6.3. Calcium Channel Blockers
  • 6.4. Organic Nitrates
  • 6.5. Potassium Channel Openers
  • 6.6. B-Blockers

7. Anti-Ischemic Agents Market, by Indication

  • 7.1. Introduction
  • 7.2. Angina Pectoris
  • 7.3. Ischemic Stroke
  • 7.4. Myocardial Infarction
  • 7.5. Peripheral Artery Diseases

8. Anti-Ischemic Agents Market, by Route of Administration

  • 8.1. Introduction
  • 8.2. Intravenous (IV)
  • 8.3. Oral
  • 8.4. Transdermal

9. Anti-Ischemic Agents Market, by End-User

  • 9.1. Introduction
  • 9.2. Ambulatory Care
  • 9.3. Homecare
  • 9.4. Hospitals

10. Americas Anti-Ischemic Agents Market

  • 10.1. Introduction
  • 10.2. Argentina
  • 10.3. Brazil
  • 10.4. Canada
  • 10.5. Mexico
  • 10.6. United States

11. Asia-Pacific Anti-Ischemic Agents Market

  • 11.1. Introduction
  • 11.2. Australia
  • 11.3. China
  • 11.4. India
  • 11.5. Indonesia
  • 11.6. Japan
  • 11.7. Malaysia
  • 11.8. Philippines
  • 11.9. Singapore
  • 11.10. South Korea
  • 11.11. Taiwan
  • 11.12. Thailand
  • 11.13. Vietnam

12. Europe, Middle East & Africa Anti-Ischemic Agents Market

  • 12.1. Introduction
  • 12.2. Denmark
  • 12.3. Egypt
  • 12.4. Finland
  • 12.5. France
  • 12.6. Germany
  • 12.7. Israel
  • 12.8. Italy
  • 12.9. Netherlands
  • 12.10. Nigeria
  • 12.11. Norway
  • 12.12. Poland
  • 12.13. Qatar
  • 12.14. Russia
  • 12.15. Saudi Arabia
  • 12.16. South Africa
  • 12.17. Spain
  • 12.18. Sweden
  • 12.19. Switzerland
  • 12.20. Turkey
  • 12.21. United Arab Emirates
  • 12.22. United Kingdom

13. Competitive Landscape

  • 13.1. Market Share Analysis, 2023
  • 13.2. FPNV Positioning Matrix, 2023
  • 13.3. Competitive Scenario Analysis
  • 13.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. Alembic Pharmaceuticals Limited
  • 2. AstraZeneca
  • 3. Baxter, Inc.
  • 4. Bayer AG
  • 5. Boehringer Ingelheim
  • 6. Bristol Myers Squibb
  • 7. Cipla Ltd.
  • 8. Dr Reddy's Laboratories Ltd.
  • 9. Eli Lily & Company
  • 10. Eris Lifesciences Ltd.
  • 11. FDC Ltd.
  • 12. Glenmark Pharmaceuticals Ltd.
  • 13. Intas Pharmaceuticals Ltd.
  • 14. Ipca Laboratories Ltd.
  • 15. J B Chemicals and Pharmaceuticals Ltd.
  • 16. Lupin Ltd.
  • 17. Macleods Pharmaceuticals Pvt Ltd.
  • 18. Medley Pharmaceuticals Ltd.
  • 19. Micro Labs Ltd.
  • 20. Natco Pharma Ltd.
  • 21. Novartis AG
  • 22. Pfizer, Inc.
  • 23. Torrent Pharmaceuticals Ltd.
  • 24. Troikaa Pharmaceuticals Ltd.
  • 25. Zydus Lifesciences Ltd.

LIST OF FIGURES

  • FIGURE 1. ANTI-ISCHEMIC AGENTS MARKET RESEARCH PROCESS
  • FIGURE 2. ANTI-ISCHEMIC AGENTS MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL ANTI-ISCHEMIC AGENTS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL ANTI-ISCHEMIC AGENTS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL ANTI-ISCHEMIC AGENTS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL ANTI-ISCHEMIC AGENTS MARKET SIZE, BY TYPE, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL ANTI-ISCHEMIC AGENTS MARKET SIZE, BY TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL ANTI-ISCHEMIC AGENTS MARKET SIZE, BY INDICATION, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL ANTI-ISCHEMIC AGENTS MARKET SIZE, BY INDICATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL ANTI-ISCHEMIC AGENTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL ANTI-ISCHEMIC AGENTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. GLOBAL ANTI-ISCHEMIC AGENTS MARKET SIZE, BY END-USER, 2023 VS 2030 (%)
  • FIGURE 13. GLOBAL ANTI-ISCHEMIC AGENTS MARKET SIZE, BY END-USER, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. AMERICAS ANTI-ISCHEMIC AGENTS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 15. AMERICAS ANTI-ISCHEMIC AGENTS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. UNITED STATES ANTI-ISCHEMIC AGENTS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 17. UNITED STATES ANTI-ISCHEMIC AGENTS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. ASIA-PACIFIC ANTI-ISCHEMIC AGENTS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 19. ASIA-PACIFIC ANTI-ISCHEMIC AGENTS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. EUROPE, MIDDLE EAST & AFRICA ANTI-ISCHEMIC AGENTS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 21. EUROPE, MIDDLE EAST & AFRICA ANTI-ISCHEMIC AGENTS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 22. ANTI-ISCHEMIC AGENTS MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 23. ANTI-ISCHEMIC AGENTS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. ANTI-ISCHEMIC AGENTS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL ANTI-ISCHEMIC AGENTS MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL ANTI-ISCHEMIC AGENTS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL ANTI-ISCHEMIC AGENTS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. ANTI-ISCHEMIC AGENTS MARKET DYNAMICS
  • TABLE 7. GLOBAL ANTI-ISCHEMIC AGENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL ANTI-ISCHEMIC AGENTS MARKET SIZE, BY ANTIPLATELET AGENTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL ANTI-ISCHEMIC AGENTS MARKET SIZE, BY CALCIUM CHANNEL BLOCKERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL ANTI-ISCHEMIC AGENTS MARKET SIZE, BY ORGANIC NITRATES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL ANTI-ISCHEMIC AGENTS MARKET SIZE, BY POTASSIUM CHANNEL OPENERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL ANTI-ISCHEMIC AGENTS MARKET SIZE, BY B-BLOCKERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL ANTI-ISCHEMIC AGENTS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL ANTI-ISCHEMIC AGENTS MARKET SIZE, BY ANGINA PECTORIS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL ANTI-ISCHEMIC AGENTS MARKET SIZE, BY ISCHEMIC STROKE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL ANTI-ISCHEMIC AGENTS MARKET SIZE, BY MYOCARDIAL INFARCTION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL ANTI-ISCHEMIC AGENTS MARKET SIZE, BY PERIPHERAL ARTERY DISEASES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL ANTI-ISCHEMIC AGENTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL ANTI-ISCHEMIC AGENTS MARKET SIZE, BY INTRAVENOUS (IV), BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL ANTI-ISCHEMIC AGENTS MARKET SIZE, BY ORAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL ANTI-ISCHEMIC AGENTS MARKET SIZE, BY TRANSDERMAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL ANTI-ISCHEMIC AGENTS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 23. GLOBAL ANTI-ISCHEMIC AGENTS MARKET SIZE, BY AMBULATORY CARE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 24. GLOBAL ANTI-ISCHEMIC AGENTS MARKET SIZE, BY HOMECARE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 25. GLOBAL ANTI-ISCHEMIC AGENTS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 26. AMERICAS ANTI-ISCHEMIC AGENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 27. AMERICAS ANTI-ISCHEMIC AGENTS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 28. AMERICAS ANTI-ISCHEMIC AGENTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 29. AMERICAS ANTI-ISCHEMIC AGENTS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 30. AMERICAS ANTI-ISCHEMIC AGENTS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 31. ARGENTINA ANTI-ISCHEMIC AGENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 32. ARGENTINA ANTI-ISCHEMIC AGENTS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 33. ARGENTINA ANTI-ISCHEMIC AGENTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 34. ARGENTINA ANTI-ISCHEMIC AGENTS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 35. BRAZIL ANTI-ISCHEMIC AGENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 36. BRAZIL ANTI-ISCHEMIC AGENTS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 37. BRAZIL ANTI-ISCHEMIC AGENTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 38. BRAZIL ANTI-ISCHEMIC AGENTS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 39. CANADA ANTI-ISCHEMIC AGENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 40. CANADA ANTI-ISCHEMIC AGENTS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 41. CANADA ANTI-ISCHEMIC AGENTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 42. CANADA ANTI-ISCHEMIC AGENTS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 43. MEXICO ANTI-ISCHEMIC AGENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 44. MEXICO ANTI-ISCHEMIC AGENTS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 45. MEXICO ANTI-ISCHEMIC AGENTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 46. MEXICO ANTI-ISCHEMIC AGENTS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 47. UNITED STATES ANTI-ISCHEMIC AGENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 48. UNITED STATES ANTI-ISCHEMIC AGENTS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 49. UNITED STATES ANTI-ISCHEMIC AGENTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 50. UNITED STATES ANTI-ISCHEMIC AGENTS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 51. UNITED STATES ANTI-ISCHEMIC AGENTS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 52. ASIA-PACIFIC ANTI-ISCHEMIC AGENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 53. ASIA-PACIFIC ANTI-ISCHEMIC AGENTS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 54. ASIA-PACIFIC ANTI-ISCHEMIC AGENTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 55. ASIA-PACIFIC ANTI-ISCHEMIC AGENTS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 56. ASIA-PACIFIC ANTI-ISCHEMIC AGENTS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 57. AUSTRALIA ANTI-ISCHEMIC AGENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 58. AUSTRALIA ANTI-ISCHEMIC AGENTS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 59. AUSTRALIA ANTI-ISCHEMIC AGENTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 60. AUSTRALIA ANTI-ISCHEMIC AGENTS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 61. CHINA ANTI-ISCHEMIC AGENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 62. CHINA ANTI-ISCHEMIC AGENTS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 63. CHINA ANTI-ISCHEMIC AGENTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 64. CHINA ANTI-ISCHEMIC AGENTS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 65. INDIA ANTI-ISCHEMIC AGENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 66. INDIA ANTI-ISCHEMIC AGENTS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 67. INDIA ANTI-ISCHEMIC AGENTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 68. INDIA ANTI-ISCHEMIC AGENTS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 69. INDONESIA ANTI-ISCHEMIC AGENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 70. INDONESIA ANTI-ISCHEMIC AGENTS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 71. INDONESIA ANTI-ISCHEMIC AGENTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 72. INDONESIA ANTI-ISCHEMIC AGENTS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 73. JAPAN ANTI-ISCHEMIC AGENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 74. JAPAN ANTI-ISCHEMIC AGENTS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 75. JAPAN ANTI-ISCHEMIC AGENTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 76. JAPAN ANTI-ISCHEMIC AGENTS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 77. MALAYSIA ANTI-ISCHEMIC AGENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 78. MALAYSIA ANTI-ISCHEMIC AGENTS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 79. MALAYSIA ANTI-ISCHEMIC AGENTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 80. MALAYSIA ANTI-ISCHEMIC AGENTS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 81. PHILIPPINES ANTI-ISCHEMIC AGENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 82. PHILIPPINES ANTI-ISCHEMIC AGENTS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 83. PHILIPPINES ANTI-ISCHEMIC AGENTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 84. PHILIPPINES ANTI-ISCHEMIC AGENTS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 85. SINGAPORE ANTI-ISCHEMIC AGENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 86. SINGAPORE ANTI-ISCHEMIC AGENTS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 87. SINGAPORE ANTI-ISCHEMIC AGENTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 88. SINGAPORE ANTI-ISCHEMIC AGENTS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 89. SOUTH KOREA ANTI-ISCHEMIC AGENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 90. SOUTH KOREA ANTI-ISCHEMIC AGENTS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 91. SOUTH KOREA ANTI-ISCHEMIC AGENTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 92. SOUTH KOREA ANTI-ISCHEMIC AGENTS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 93. TAIWAN ANTI-ISCHEMIC AGENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 94. TAIWAN ANTI-ISCHEMIC AGENTS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 95. TAIWAN ANTI-ISCHEMIC AGENTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 96. TAIWAN ANTI-ISCHEMIC AGENTS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 97. THAILAND ANTI-ISCHEMIC AGENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 98. THAILAND ANTI-ISCHEMIC AGENTS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 99. THAILAND ANTI-ISCHEMIC AGENTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 100. THAILAND ANTI-ISCHEMIC AGENTS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 101. VIETNAM ANTI-ISCHEMIC AGENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 102. VIETNAM ANTI-ISCHEMIC AGENTS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 103. VIETNAM ANTI-ISCHEMIC AGENTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 104. VIETNAM ANTI-ISCHEMIC AGENTS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 105. EUROPE, MIDDLE EAST & AFRICA ANTI-ISCHEMIC AGENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 106. EUROPE, MIDDLE EAST & AFRICA ANTI-ISCHEMIC AGENTS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 107. EUROPE, MIDDLE EAST & AFRICA ANTI-ISCHEMIC AGENTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 108. EUROPE, MIDDLE EAST & AFRICA ANTI-ISCHEMIC AGENTS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 109. EUROPE, MIDDLE EAST & AFRICA ANTI-ISCHEMIC AGENTS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 110. DENMARK ANTI-ISCHEMIC AGENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 111. DENMARK ANTI-ISCHEMIC AGENTS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 112. DENMARK ANTI-ISCHEMIC AGENTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 113. DENMARK ANTI-ISCHEMIC AGENTS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 114. EGYPT ANTI-ISCHEMIC AGENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 115. EGYPT ANTI-ISCHEMIC AGENTS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 116. EGYPT ANTI-ISCHEMIC AGENTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 117. EGYPT ANTI-ISCHEMIC AGENTS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 118. FINLAND ANTI-ISCHEMIC AGENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 119. FINLAND ANTI-ISCHEMIC AGENTS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 120. FINLAND ANTI-ISCHEMIC AGENTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 121. FINLAND ANTI-ISCHEMIC AGENTS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 122. FRANCE ANTI-ISCHEMIC AGENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 123. FRANCE ANTI-ISCHEMIC AGENTS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 124. FRANCE ANTI-ISCHEMIC AGENTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 125. FRANCE ANTI-ISCHEMIC AGENTS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 126. GERMANY ANTI-ISCHEMIC AGENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 127. GERMANY ANTI-ISCHEMIC AGENTS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 128. GERMANY ANTI-ISCHEMIC AGENTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 129. GERMANY ANTI-ISCHEMIC AGENTS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 130. ISRAEL ANTI-ISCHEMIC AGENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 131. ISRAEL ANTI-ISCHEMIC AGENTS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 132. ISRAEL ANTI-ISCHEMIC AGENTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 133. ISRAEL ANTI-ISCHEMIC AGENTS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 134. ITALY ANTI-ISCHEMIC AGENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 135. ITALY ANTI-ISCHEMIC AGENTS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 136. ITALY ANTI-ISCHEMIC AGENTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 137. ITALY ANTI-ISCHEMIC AGENTS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 138. NETHERLANDS ANTI-ISCHEMIC AGENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 139. NETHERLANDS ANTI-ISCHEMIC AGENTS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 140. NETHERLANDS ANTI-ISCHEMIC AGENTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 141. NETHERLANDS ANTI-ISCHEMIC AGENTS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 142. NIGERIA ANTI-ISCHEMIC AGENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 143. NIGERIA ANTI-ISCHEMIC AGENTS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 144. NIGERIA ANTI-ISCHEMIC AGENTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 145. NIGERIA ANTI-ISCHEMIC AGENTS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 146. NORWAY ANTI-ISCHEMIC AGENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 147. NORWAY ANTI-ISCHEMIC AGENTS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 148. NORWAY ANTI-ISCHEMIC AGENTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 149. NORWAY ANTI-ISCHEMIC AGENTS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 150. POLAND ANTI-ISCHEMIC AGENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 151. POLAND ANTI-ISCHEMIC AGENTS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 152. POLAND ANTI-ISCHEMIC AGENTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 153. POLAND ANTI-ISCHEMIC AGENTS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 154. QATAR ANTI-ISCHEMIC AGENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 155. QATAR ANTI-ISCHEMIC AGENTS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 156. QATAR ANTI-ISCHEMIC AGENTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 157. QATAR ANTI-ISCHEMIC AGENTS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 158. RUSSIA ANTI-ISCHEMIC AGENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 159. RUSSIA ANTI-ISCHEMIC AGENTS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 160. RUSSIA ANTI-ISCHEMIC AGENTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 161. RUSSIA ANTI-ISCHEMIC AGENTS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 162. SAUDI ARABIA ANTI-ISCHEMIC AGENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 163. SAUDI ARABIA ANTI-ISCHEMIC AGENTS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 164. SAUDI ARABIA ANTI-ISCHEMIC AGENTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 165. SAUDI ARABIA ANTI-ISCHEMIC AGENTS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 166. SOUTH AFRICA ANTI-ISCHEMIC AGENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 167. SOUTH AFRICA ANTI-ISCHEMIC AGENTS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 168. SOUTH AFRICA ANTI-ISCHEMIC AGENTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 169. SOUTH AFRICA ANTI-ISCHEMIC AGENTS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 170. SPAIN ANTI-ISCHEMIC AGENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 171. SPAIN ANTI-ISCHEMIC AGENTS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 172. SPAIN ANTI-ISCHEMIC AGENTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 173. SPAIN ANTI-ISCHEMIC AGENTS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 174. SWEDEN ANTI-ISCHEMIC AGENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 175. SWEDEN ANTI-ISCHEMIC AGENTS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 176. SWEDEN ANTI-ISCHEMIC AGENTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 177. SWEDEN ANTI-ISCHEMIC AGENTS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 178. SWITZERLAND ANTI-ISCHEMIC AGENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 179. SWITZERLAND ANTI-ISCHEMIC AGENTS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 180. SWITZERLAND ANTI-ISCHEMIC AGENTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 181. SWITZERLAND ANTI-ISCHEMIC AGENTS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 182. TURKEY ANTI-ISCHEMIC AGENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 183. TURKEY ANTI-ISCHEMIC AGENTS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 184. TURKEY ANTI-ISCHEMIC AGENTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 185. TURKEY ANTI-ISCHEMIC AGENTS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 186. UNITED ARAB EMIRATES ANTI-ISCHEMIC AGENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 187. UNITED ARAB EMIRATES ANTI-ISCHEMIC AGENTS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 188. UNITED ARAB EMIRATES ANTI-ISCHEMIC AGENTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 189. UNITED ARAB EMIRATES ANTI-ISCHEMIC AGENTS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 190. UNITED KINGDOM ANTI-ISCHEMIC AGENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 191. UNITED KINGDOM ANTI-ISCHEMIC AGENTS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 192. UNITED KINGDOM ANTI-ISCHEMIC AGENTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 193. UNITED KINGDOM ANTI-ISCHEMIC AGENTS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 194. ANTI-ISCHEMIC AGENTS MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 195. ANTI-ISCHEMIC AGENTS MARKET, FPNV POSITIONING MATRIX, 2023